Amit Kumar Tiwari
Senior Patent Associate
faculty
COP | College of Pharmacy
Research Areas
Biography and Research Information
OverviewAI-generated summary
Dr. Amit Kumar Tiwari's research interests span chemistry, patent law, and science communication. He holds degrees in Science, Pharmaceutical Chemistry, and a Ph.D. in Chemistry with a specialization in Medicinal Chemistry. His postgraduate studies include Cheminformatics and Patent Law, complemented by certifications in Intellectual Property Management, Intellectual Property and Cyber Law, competitive intelligence, and innovation management.
Dr. Tiwari's recent publications indicate a focus on environmental contamination, including nutrient and micro-plastic pollution in various ecosystems, and patent landscape analyses of materials like poly-4-methyl-1-pentene and constructed wetlands for wastewater treatment. He has also published on breast cancer theranostics and digital health technologies, alongside reviews on polymer brushes for smart materials. His work in these areas is supported by a scholarly output reflected in an h-index of 12 and over 790 citations across 131 publications.
His professional activities include serving as a Senior Patent Associate at the University of Arkansas for Medical Sciences. He has a significant number of shared publications with a collaborator also named Amit K. Tiwari from the same institution, indicating a collaborative research network within UAMS.
Metrics
- h-index: 46
- Publications: 390
- Citations: 8,471
Selected Publications
-
Stability of Ketamine-Xylazine-Butorphanol formulation to establish an evidence-based beyond-use date (2026)
-
Targeting Microbiome-Derived Exosomes to Overcome Cancer Therapy Resistance: Mechanisms, Implications, and Opportunities (2025)
-
Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer (2025)
-
Strategies to Combat Resistance to Anti-angiogenesis Therapies in Cancer: Current Status and Future Prospects (2025)
-
Synergistic strategies: histone deacetylase inhibitors and platinum-based drugs in cancer therapy (2025)
-
Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery (2024)
-
Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives (2024)
-
Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants (2024)
-
Dietary Plant Metabolites Induced Epigenetic Modification as a NovelStrategy for the Management of Prostate Cancer (2024)
-
Targeting Lysosomes: A Strategy Against Chemoresistance in Cancer (2024)
-
Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A (2024)
-
The Role of Cytokines in Activation of Tumour-promoting Pathways andEmergence of Cancer Drug Resistance (2024)
-
Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges (2023)
-
Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy (2023)
-
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment (2023)
Research Interests
Dr. Tiwari is an Associate Dean of Research & Graduate Studies and a Professor of Pharmaceutical Sciences in the College of Pharmacy at University of Arkansas for Medical Sciences, Arkansas. He is a seasoned pharmacologist, a board-certified toxicologist and also leads a funded ?Cancer and Systems Therapeutics (CAST) program. He has been widely cited and has published, over 240 peer reviewed publications, patents and book chapters. CAST team is involved in a) developing effective, safe, and targeted anticancer molecules against multidrug-resistant cancers; b) designing, synthesizing and characterizing non-conventional forms of cell death inducers. CAST team has discovered first-in-class, safe agents that activate necroptosis, methuosis, methuophagy, ferroptosis, entosis, and immunogenic cell death, sensitizing resistant cancers to immuno- and radiotherapies. Integrating biomimetic microfluidics, high-content imaging, and AI-driven analytics, his group develops predictive tools to understand and overcome chemotherapy failure. In parallel, they are advancing patented macropinocytosis-based delivery platforms that enhance intracellular transport of siRNAs and proteins. Supported by multiple federal and foundation grants, issued patents, and international collaborations, Dr. Tiwari’s translational program bridges preclinical innovation with therapeutic impact.; Drug Discovery; Drug Resistance; Non Apoptotic Cell Death; Formulations, Drug; Drug Delivery Systems; Intellectual Properties
Grants & Funding
- Development of Novel Inducers of Non-Apoptotic Cell Death to Target TNBC US Department of Defense Principal Investigator
- High-throughput high-resolution microscopy for phenotypic drug discovery applications NIH/Nat. Inst. of Biomedical Imaging & Bioengineering - Pass Through: University of Toledo Principal Investigator
- ABI A. Tiwari Startup FY26 Y3 State of Arkansas Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics